Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Massart J, Begriche K, Moreau C, Fromenty B.

J Clin Transl Res. 2017 Feb;3(Suppl 1):212-232. doi: 10.18053/jctres.03.2017S1.006. Epub 2017 Feb 12.

2.
3.

First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.

Castelnuovo B, Kiragga A, Mubiru F, Kambugu A, Kamya M, Reynolds SJ.

J Int AIDS Soc. 2016 Jun 17;19(1):20773. doi: 10.7448/IAS.19.1.20773. eCollection 2016.

4.

Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria.

Oreagba IA, Usman SO, Olayemi SO, Oshikoya KA, Opanuga O, Adeyemo TA, Lesi OA, Dodoo AN, Akanmu AS.

Ghana Med J. 2014 Dec;48(4):194-203.

5.

Zidovudine as modern day salvage therapy for HIV infection.

Kupiec KE, Johnson JW, Barroso LF, Wrenn RH, Williamson JC.

AIDS Patient Care STDS. 2014 Nov;28(11):570-4. doi: 10.1089/apc.2014.0151.

6.

Incidence and predictors of first line antiretroviral regimen modification in western Kenya.

Inzaule S, Otieno J, Kalyango J, Nafisa L, Kabugo C, Nalusiba J, Kwaro D, Zeh C, Karamagi C.

PLoS One. 2014 Apr 2;9(4):e93106. doi: 10.1371/journal.pone.0093106. eCollection 2014.

7.

Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.

Mamiafo CT, Moor VJ, Nansseu JR, Pieme CA, Tayou C, Yonkeu JN.

AIDS Res Ther. 2014 Jan 15;11(1):2. doi: 10.1186/1742-6405-11-2.

8.

Etiology and therapeutic approach to elevated lactate levels.

Andersen LW, Mackenhauer J, Roberts JC, Berg KM, Cocchi MN, Donnino MW.

Mayo Clin Proc. 2013 Oct;88(10):1127-40. doi: 10.1016/j.mayocp.2013.06.012. Review.

9.

Longitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicities.

Chagoma N, Mallewa J, Kaunda S, Njalale Y, Kampira E, Mukaka M, Heyderman RS, van Oosterhout JJ.

Trans R Soc Trop Med Hyg. 2013 Oct;107(10):615-9. doi: 10.1093/trstmh/trt074. Epub 2013 Aug 7.

10.

Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana.

Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, Musonda R, van Widenfelt E, Novitsky V, Makhema J, Marlink RG, Essex M, Wester CW.

J Antivir Antiretrovir. 2011 Oct;3(4):45-48. Epub 2011 Sep 20.

11.

Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi.

van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, Mukaka M, Heyderman RS.

PLoS One. 2012;7(7):e42029. doi: 10.1371/journal.pone.0042029. Epub 2012 Jul 26.

12.

Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.

Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):759-65. doi: 10.1089/AID.2011.0303. Epub 2012 Jun 1.

13.

Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.

Crain MJ, Williams PL, Griner R, Tassiopoulos K, Read JS, Mofenson LM, Rich KC; Pediatric HIVAIDS Cohort Study.

Pediatr Infect Dis J. 2011 Dec;30(12):1069-74. doi: 10.1097/INF.0b013e318234c886.

14.

A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy.

Matthews LT, Giddy J, Ghebremichael M, Hampton J, Guarino AJ, Ewusi A, Carver E, Axten K, Geary MC, Gandhi RT, Bangsberg DR.

PLoS One. 2011 Apr 11;6(4):e18736. doi: 10.1371/journal.pone.0018736.

16.

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.

J Infect Dis. 2010 Nov 15;202(10):1529-37. doi: 10.1086/656718. Epub 2010 Oct 13.

17.

Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, Coulibaly A, Salamon R, Eholié S, Anglaret X, Danel C; ANRS 1220 Primo-CI Study Group.

AIDS Res Hum Retroviruses. 2010 Sep;26(9):991-5. doi: 10.1089/aid.2009.0309.

18.

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.

Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, Danel C, Sloan CE, Losina E, Freedberg KA; CEPAC-International Investigators.

Antivir Ther. 2010;15(3):351-61. doi: 10.3851/IMP1542.

19.
20.

Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.

Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk MJ, Kaufman JS, Van Rie A, Macphail P.

Clin Infect Dis. 2009 Jun 1;48(11):1617-23. doi: 10.1086/598977.

Supplemental Content

Support Center